CA2022523A1 - Fragments de peptide cd4 modifie chimiquement ayant des proprietes anti-retrovirales - Google Patents

Fragments de peptide cd4 modifie chimiquement ayant des proprietes anti-retrovirales

Info

Publication number
CA2022523A1
CA2022523A1 CA 2022523 CA2022523A CA2022523A1 CA 2022523 A1 CA2022523 A1 CA 2022523A1 CA 2022523 CA2022523 CA 2022523 CA 2022523 A CA2022523 A CA 2022523A CA 2022523 A1 CA2022523 A1 CA 2022523A1
Authority
CA
Canada
Prior art keywords
polypeptide
peptide
hiv
group
bzl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2022523
Other languages
English (en)
Inventor
Jeffrey D. Lifson
Kou Hwang
Lee E. Eiden
Blair Fraser
Peter L. Nara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Genelabs Inc
Original Assignee
US Department of Health and Human Services
Genelabs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Genelabs Inc filed Critical US Department of Health and Human Services
Publication of CA2022523A1 publication Critical patent/CA2022523A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA 2022523 1989-05-02 1990-08-02 Fragments de peptide cd4 modifie chimiquement ayant des proprietes anti-retrovirales Abandoned CA2022523A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34615989A 1989-05-02 1989-05-02
US50383290A 1990-04-03 1990-04-03
US503,832 1990-04-03

Publications (1)

Publication Number Publication Date
CA2022523A1 true CA2022523A1 (fr) 1991-10-04

Family

ID=26994724

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2022523 Abandoned CA2022523A1 (fr) 1989-05-02 1990-08-02 Fragments de peptide cd4 modifie chimiquement ayant des proprietes anti-retrovirales

Country Status (4)

Country Link
EP (1) EP0462229A4 (fr)
AU (1) AU5656890A (fr)
CA (1) CA2022523A1 (fr)
WO (1) WO1990013562A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2021943A6 (es) * 1990-02-09 1991-11-16 Inst Cientifico Tecnol Navarra Procedimiento para la sintesis de peptidos para neutralizar la infectividad del virus del sida (vhs)
CA2041271A1 (fr) * 1990-04-30 1991-10-31 Bradford A. Jameson Peptides analogues aux proteines de la grande famille des immunoglobines
AU2143292A (en) * 1991-05-21 1992-12-30 Board Of Trustees Of The University Of Illinois, The Peptidomimetic inhibitors of hiv gp120 binding to cd4
AU4396693A (en) * 1992-05-28 1993-12-30 Board Of Trustees Of The University Of Illinois, The Design and synthesis of a CD4 beta-turn mimetic for inhibiting the binding of HIV GP120
FR2694560B1 (fr) * 1992-08-10 1995-06-30 Zagury Jean Francois Nouveaux peptides viraux, anticorps diriges contre ces peptides, procede de preparation, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
US5696229A (en) * 1995-03-16 1997-12-09 The University Of Virginia Patent Foundation Polypeptide with laminin cell adhesion and morphogenesis activity
EP1460088A1 (fr) 2003-03-21 2004-09-22 Biotest AG Anticorps humanisé contre CD4 avec des caractéristiques immunosuppressives
BRPI0909180A2 (pt) 2008-03-13 2016-08-09 Biotest Ag composição farmacêutica, e, método de tratamento de uma doença autoimune
AU2009231325B2 (en) 2008-03-13 2014-09-18 Biotest Ag Agent for treating disease
ES2610327T3 (es) 2008-03-13 2017-04-27 Biotest Ag Régimen de dosificación de anticuerpos anti-CD4 para el tratamiento de enfermedades autoinmunitarias
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4260681A (en) * 1978-12-28 1981-04-07 Calbiochem-Behring Corp. Reagent system and method for assaying peptidase enzymes
GB8305985D0 (en) * 1983-03-04 1983-04-07 Szelke M Enzyme inhibition
WO1989003420A1 (fr) * 1987-10-13 1989-04-20 Genelabs Incorporated Agent anti-retroviral
WO1989009782A1 (fr) * 1987-10-14 1989-10-19 United States Of America, Represented By The Secre Nouveaux peptides anti-recepteurs et agents therapeutiques

Also Published As

Publication number Publication date
AU5656890A (en) 1990-11-29
EP0462229A1 (fr) 1991-12-27
WO1990013562A1 (fr) 1990-11-15
EP0462229A4 (en) 1992-03-11

Similar Documents

Publication Publication Date Title
CA2091263C (fr) Peptides utilises pour la vaccination et l'induction d'anticorps neutralisants contre le virus de l'immunodeficience humaine
EP2035453B1 (fr) Peptides mimetiques des cd4 et utilisations de ceux-ci
CA2022523A1 (fr) Fragments de peptide cd4 modifie chimiquement ayant des proprietes anti-retrovirales
US5627035A (en) Peptides that block human immunodeficiency virus and methods of use thereof
AU2002233424B2 (en) Peptides having affinity for the GP120 viral protein and use thereof
US5346989A (en) Peptides for use in induction of T cell activation against HIV-1
AP502A (en) Multiple branch peptide constructions for use against HIV.
EP0394297A1 (fr) Agent anti-retroviral
AU631357B2 (en) New anti-receptor peptides and therapeutic agents
CN109311910B (zh) 他克莫司偶联物、其组合物、及其用途
WO1989003221A1 (fr) Agent antisyncytial
Morrow et al. Synthetic peptides from a conserved region of gp120 induce broadly reactive anti-HIV responses.
AU662534B2 (en) Peptides for use in induction of T cell activation against HIV-1
WO1992009625A1 (fr) Peptide i de configuration restreinte
Rausch et al. CD4 (81–92)-based peptide derivatives: Structural requirements for blockade of HIV infection, blockade of HIV-induced syncytium formation, and virostatic activity in vitro
KR100447943B1 (ko) Ｈｉｖ의 감염 억제 펩타이드
JP3115596B2 (ja) ヒト免疫不全ウィルス感染を阻止するペプチドとその使用法
Murakami et al. Applications of biotinylated V3 loop peptides of human immunodeficiency virus type 1 to flow cytometric analyses and affinity chromatographic techniques
AU6515394A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
BAHRAOUI et al. Accessibility of the highly conserved amino-and carboxy-terminal regions from HIV-1 external envelope glycoproteins
Goetz et al. Synthesis and CD studies of an 88‐residue peptide containing the main receptor binding site of HTLV‐I SU‐glycoprotein
CA2171531C (fr) Constructions peptidiques a ramifications multiples, utiles contre le vih
Cereda et al. Anti-HIV-1 activity of CD4 synthetic oligopeptides representative of the putative gp120 binding site
JPH03501847A (ja) 抗‐レトロウィルス剤
Syennerholm et al. Vahlne et al.

Legal Events

Date Code Title Description
FZDE Dead